CELL INTELLIGENCE · 肿瘤细胞治疗研究

膀胱癌免疫治疗的最新进展：机制、临床应用与未来展望

Recent advances in immunotherapy for bladder cancer: mechanisms, clinical applications, and future perspectives.

CAR-T 细胞治疗膀胱癌的进展与挑战

Progress and challenges in CAR-T cell therapy for bladder cancer.

泌尿系统肿瘤中的 NK 细胞与 CAR-NK 细胞治疗：进展、来自 CAR-T 的机制启示及未来方向

Natural killer and CAR-NK cell therapies in urological cancers: Progress, mechanistic lessons from CAR-T, and future directions.

基于嵌合抗原受体的细胞治疗用于泌尿系统肿瘤

Chimeric antigen receptor-based cell therapy for treating urological tumors.

双特异性 c-Met/PD-1 CAR-T 细胞对实体瘤具有增强的治疗效果

Bispecific c-Met/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor.

免疫肿瘤治疗药物的临床开发

Clinical development of immuno-oncology therapeutics.

特异性靶向 SIA-CIgG 的新型 CAR-T 细胞在膀胱癌中展现有效抗肿瘤疗效

Novel CAR-T Cells Specifically Targeting SIA-CIgG Demonstrate Effective Antitumor Efficacy in Bladder Cancer.

CAR-T 细胞治疗泌尿系统肿瘤的分子认识与临床结局

Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors.

患者来源的膀胱癌类器官模型用于预测定制精准治疗的敏感性和可行性

Patient-derived bladder cancer organoid model to predict sensitivity and feasibility of tailored precision therapy.

我们的研究凸显了 BCO 在促进膀胱癌个体化医疗发展、提高膀胱癌治疗药物研发效率方面的潜力。

MST1R 作为 CAR-T 细胞治疗实体瘤的潜在新靶抗原

MST1R as a potential new target antigen of chimeric antigen receptor T cells to treat solid tumors.